Logo of Memphasys (ASX:MEM)Latest Memphasys (ASX:MEM) News

Page 2
Page 2 of 7

Memphasys Accelerates Thai Market Entry with Early Felix™ Approval and Expanding Orders

Memphasys has secured early Thai FDA approval for its Felix™ System, triggering a three-year exclusive distribution deal with IVF Envimed and prompting additional orders amid strong clinic interest.
Ada Torres
28 Aug 2026

Healthcare Wrap - Week 34 (17 Aug -> 21 Aug) 2026

Healthcare shares delivered a mixed week, with strong gains at AVITA Medical, Australian Clinical Labs and CSL despite very different company results.
Investors also weighed new US approvals, clinical trial progress, funding needs and rising sales across the sector.
Logan Eniac
22 Aug 2026

Memphasys Secures Vietnam Registration and Triggers 600-Cartridge Felix Order

Memphasys has cleared a key regulatory hurdle in Vietnam for its Felix™ System, prompting a significant first commercial cartridge order and marking early clinical success in a fast-growing fertility market.
Ada Torres
20 Aug 2026

Healthcare Wrap - Week 32 (3 Aug -> 7 Aug) 2026

Wellnex led the healthcare market after agreeing to sell Pain Away for up to A$21.3 million. Neuren and Lumos also rose strongly as sales, royalties and product orders improved.
Logan Eniac
8 Aug 2026

Memphasys Expands Felix™ Reach with A$350,000 Polish Deal

Memphasys secures exclusive Felix™ commercialisation agreement in Poland, marking its third European market entry with a two-year contract valued at approximately A$350,000.
Ada Torres
5 Aug 2026

Market Wrap - Week 29 (13 July -> 17 July) 2026

Wild swings hit the ASX this week, with Janus Electric doubling, Aura sliding almost 30%, and TechGen jumping more than 22%. Big news kept landing, but many stocks still fell as early gains faded and traders locked in profits.
Logan Eniac
18 July 2026

Healthcare Wrap - Week 29 (13 July -> 17 July) 2026

Big price swings hit healthcare stocks this week, but the sharpest falls did not always match the news flow. Revenue growth, trial progress and fresh US deals kept buying interest alive across parts of the sector.
Logan Eniac
18 July 2026

Memphasys Posts Record Quarterly Revenue and Seals Largest Felix™ Deal with Monash IVF

Memphasys delivered a record $150,000 quarterly revenue, secured its largest Felix™ supply contract with Monash IVF, and expanded into UK and Southeast Asian IVF markets, positioning for accelerated growth in FY27.
Ada Torres
16 July 2026

Healthcare Wrap - Week 27 (29 June -> 3 July) 2026

Cann Group, OncoSil and Imugene led a busy healthcare week as investors chased FDA steps, cancer trial news and balance-sheet fixes. Elsewhere, revenue growth, hospital contracts and fresh funding kept money flowing into names with near-term commercial milestones.
Logan Eniac
4 July 2026

Memphasys Secures A$430K Felix™ Distribution Deal in Thailand IVF Market

Memphasys has locked in a three-year exclusive distribution agreement for its Felix™ sperm separation system in Thailand, targeting a key IVF market with 110 clinics and 20,000–30,000 cycles annually. The deal adds approximately A$430,500 in contracted revenue, lifting South-East Asian minimum contracts to about A$1 million and contributing to FY2026 Felix™ sales now exceeding A$3 million.
Ada Torres
1 July 2026

Healthcare Wrap - Week 26 (22 June -> 26 June) 2026

AI cardiology, cancer research and pharma expansion drove the biggest moves in healthcare stocks this week. Investors paid up for fresh funding and regulatory wins, while some raisings and weak trading updates kept pressure on others.
Logan Eniac
27 June 2026

Memphasys Gains Swift UK Traction with Felix™ System Trials and Early Orders

Memphasys has rapidly established a foothold in the UK IVF market, securing four active commercial trials and initial orders for its Felix™ sperm selection system within weeks of launch. This momentum aligns with its global expansion strategy targeting major fertility markets.
Ada Torres
25 June 2026